

7 November 2025

Privatisation by way of scheme of arrangement

Disclosure of dealings in the shares of Kangji Medical Holdings Limited

The Executive received the following disclosure of securities dealings pursuant to Rule 22 of the Hong Kong Code on Takeovers and Mergers:

Party	Date	Description of	Description of	Nature of dealings	Number of	Maturity date /	Reference	Total amount	Resultant
		relevant	products		reference	closing out	price	paid / received	balance
		securities			securities to	date			(including those
					which the				of any person
					derivatives				with whom there
					relate				is an agreement
									or
									understanding)
J.P. Morgan	6 November	Derivatives	Other types of	Issue of a derivative	77,000	10 February	\$9.0682	\$698,251.4000	10,000,343
Securities	2025		products			2026			
PLC		Derivatives	Other types of	Closing out of a	15,500	17 July 2026	\$9.0389	\$140,103.6000	9,984,843
			products	derivative contract					
		Derivatives	Other types of	Closing out of a	156,500	17 July 2026	\$9.0389	\$1,414,594.4200	9,828,343
			products	derivative contract					
		Derivatives	Other types of	Closing out of a	212,000	17 July 2026	\$9.0389	\$1,916,255.7000	9,616,343
			products	derivative contract					



	Derivatives	Other types of	Closing out of a	23,000	17 July 2026	\$9.0389	\$207,895.6700	9,593,343
		products	derivative contract					

End

Note:

J.P. Morgan Securities PLC is a Class (5) associate connected with the Offeror.

Dealings were made for its own account.

J.P. Morgan Securities PLC is ultimately owned by JPMorgan Chase & Co..